Inhibition of the VEGF/VEGFR pathway improves survival in advanced kidney cancer: A systematic review and meta-analysis

Current Drug Targets

Volumn 16, Issue 2, 2015, Pages 164-170

  Iacovelli, Roberto ^a   Sternberg, Cora N ^b   Porta, Camillo ^c   Verzoni, Elena ^a   de Braud, Filippo ^a   Escudier, Bernard ^d   Procopio, Giuseppe ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^d INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Bevacizumab; mRCC; Overall survival; Pazopanib; Phase III trials; Sorafenib; Sunitinib

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; PAZOPANIB; SORAFENIB; SUNITINIB; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; ANGIOGENESIS INHIBITOR; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VEGFA PROTEIN, HUMAN;

ARTICLE; HAZARD RATIO; HUMAN; IMMUNOTHERAPY; KIDNEY CANCER; KIDNEY CARCINOMA; META ANALYSIS (TOPIC); OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; ANTAGONISTS AND INHIBITORS; CARCINOMA, RENAL CELL; DISEASE FREE SURVIVAL; DRUG EFFECTS; GENETICS; KIDNEY NEOPLASMS; META ANALYSIS; METABOLISM; METASTASIS; MORTALITY; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIGNAL TRANSDUCTION;

ANGIOGENESIS INHIBITORS; CARCINOMA, RENAL CELL; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE-FREE SURVIVAL; HUMANS; KIDNEY NEOPLASMS; NEOPLASM METASTASIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84946206105     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450115666141120120145     Document Type: Article

References (32)

1. American Cancer Society. Cancer Facts & Figures 2013. Atlanta: American Cancer Society; 2013
2. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013; 49: 1374-1403
3. Bray F, Ren JS, Masuyer E, Ferlay J. Estimates of global cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer 2013; 132: 1133-1145
4. Gunningham SP, Currie MJ, Han C, et al. Vascular endothelial growth factor-B and vascular endothelial growth factor-C expression in renal cell carcinomas: regulation by the von Hippel-Lindau gene and hypoxia. Cancer Res 2001; 61: 3206-3211
5. Palazzo A, Iacovelli R, Cortesi E. Past, present and future of targeted therapy in solid tumors. Curr Cancer Drug Targets 2010; 10: 433-461
6. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271-2281
7. Mekhail TM, Abou-Jawde RM, Boumerhi G, et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 2005; 23: 832-841
8. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 1996; 17: 1-12
9. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009; 339: b2535
10. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560
11. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188
12. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088-1101
13. Egger M, Davey Smith G, Schneider M, Minder C. Bias in metaanalysis detected by a simple, graphical test. BMJ 1997; 315: 629-634
14. Morris JA, Gardner MJ. Calculating confidence intervals for relative risks (odds ratios) and standardised ratios and rates. Br Med J 1988; 296: 1313-1316
15. Review Manager (RevMan) Computer program.. Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012. Available at: http://ims.cochrane.org/revman/download
16. Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009; 27: 3312-3318
17. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27: 3584-3590
18. Rini BI, Halabi S, Rosenberg JE, et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 2010; 28: 2137-2143
19. Escudier B, Bellmunt J, Négrier S, et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 2010; 28: 2144-2150
20. Sternberg CN, Hawkins RE, Wagstaff J, et al. A randomised, double- blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. Eur J Cancer 2013; 49: 1287-1296
21. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon- alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002; 20: 289-296
22. Gore ME, Szczylik C, Porta C, et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol 2009; 10: 757-763
23. European Society of Medical Oncology (ESMO) guidelines for renal cell carcinoma. Available at: http://www.esmo.org/Guidelines/Genitourinary-Cancers/Renal-Cell-Carcinoma
24. National Comprehensive Cancer Network (NCCN) guidelines for kidney cancer. Available at: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp
25. Motzer RJ, Barrios CH, Kim TM, et al. Phase II randomized trial comparing sequential first-line everolimus (EVE) and second-line sunitinib (SUN) versus first-line SUN and second-line EVE in patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2013; 31: abstr 4504
26. Iacovelli R, Santoni M, Verzoni E, et al. Everolimus and Temsirolimus Are Not the Same Second-Line in Metastatic Renal Cell Carcinoma. A Systematic Review and Meta-Analysis of Literature Data. Clin Genitourin Cancer 2014; pii: S1558-7673(14)00153-0
27. Duh MS, Dial E, Choueiri TK, et al. Cost implications of IV versus oral anti-angiogenesis therapies in patients with advanced renal cell carcinoma: retrospective claims database analysis. Curr Med Res Opin 2009; 25: 2081-2090
28. Mickisch G, Gore M, Escudier B, et al. Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib. Br J Cancer 2010; 102: 80-86
29. Ravasio R, Ortega C, Sabbatini R, Porta C. Bevacizumab plus interferon-α versus sunitinib for first-line treatment of renal cell carcinoma in Italy: a cost-minimization analysis. Clin Drug Investig 2011; 31(7): 507-517
30. Heng DY, Xie W, Bjarnason GA, et al. Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy. Cancer 2011; 117: 2637-2642
31. Garnick MB. Preserving the sanctity of overall survival for drugs approved on the basis of progression-free survival: tivozanib as a case study. J Clin Oncol 2013; 31: 3746-3748
32. Heng DYC, Choueiri TK, Lee JL, et al. A multicentered population- based analysis of outcomes of patients with metastatic renal cell carcinoma (mRCC) that do not meet eligibility criteria for clinical trials. J Clin Oncol 2012; 30: abstr 353.